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Abstract
Background: Evidence suggests that probiotics reduce rotavirus diarrhoea duration. Although there are several
probiotic strains potentially useful, daily practice is often limited by the type and number of products locally
available. In general, information about combined products is scarce. In this study we compare the effect of two
probiotic products in the treatment of diarrhoea in children less than 2 years of age.
Methods: A Randomized double-blind controlled clinical trial in children hospitalized for acute rotavirus diarrhoea,
in the Paediatric Centre Albina Patino, Cochabamba, Bolivia.
Participants were children aged 1 - 23 months, who were randomly assigned to receive one of three treatments:
Oral rehydration therapy plus placebo; Oral rehydration solution plus Saccharomyces boulardii; or Oral rehydration
solution plus a compound containing Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum and
Saccharomyces boulardii. Sample size was 20 per group and the outcomes were duration of diarrhoea, of fever, of
vomiting and of hospitalization.
Results: 64 cases finished the protocol. On admission, patients’ characteristics were similar. Median duration of
diarrhoea (p = 0.04) in children who received the single species product (58 hours) was shorter than in controls
(84.5 hrs). Comparing children that received the single probiotic product and controls showed shorter duration of
fever (18 vs 67 hrs) (p = 0.0042) and the mixed probiotic of vomiting (0 vs 42.5 hrs) (p = 0.041). There was no
effect on duration of hospitalization (p = 0.31). When experimental groups were merged, statistical significance of
changes increased (total duration of diarrhoea, fever and vomiting P = 0.025, P = 0.025 and P = 0.014, respectively).
Conclusions: Both products decreased the duration of diarrhoea compared to oral rehydration solution alone. This
decrease was significant only for the single species product which also decreased the duration of fever. With the
multiple species product there was no vomiting subsequent to the initiation of treatment. The quantity of
probiotic bacteria needed for optimum treatment of gastroenteritis remains to be determined, particularly when
multiple species are included in the product.
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Acute gastroenteritis is an infectious syndrome that
represents the first cause of hospitalization in children.
Cohort studies show that nearly all children suffer at
least one rotavirus infection before reaching 5 years of
age, independent of their socioeconomic status [1].
Below one year of age, rotavirus represents the main
etiologic agent, both in developed and developing coun-
tries [2-4]. Globally, this agent is responsible for
approximately 600.000 deaths per year [2], 82% of which
occur in less developed areas. In Latin America, rota-
virus gastroenteritis represents 16 to 52% of cases [5]
whereas in Bolivia, in 2008 the Health Sentinels System
reported that below 5 years of age rotavirus was the
main cause of severe gastroenteritis in children, affecting
all socioeconomic conditions; thus, rotavirus was
responsible for 40% of hospitalizations and 50% of
deaths [6]. In 1989, a study by Lopez et al in Cocha-
bamba, Bolivia, described that rotavirus was found in
22.5% of cases admitted for acute diarrhoeal disease [7].
More recently, a study conducted in 2007 also in
Cochabamba, confirmed the high frequency (19%) of
rotavirus in children admitted for acute diarrhoea [8].
Treatment of diarrhoea basically consists of replacing
lost fluids by means of oral rehydration solutions [9,10];
in order to minimize the nutritional impact, treatment
aims at shortening the period of fluid losses (diarrhoea
and vomiting) and total time of diarrhoea. Although
oral rehydration solutions successfully avoid death asso-
ciated with dehydration and acidosis, they are not effec-
tive in shortening the duration of rotavirus-induced
diarrhoea and of high fluid losses [11-14]. Testing differ-
ent strategies to help in this direction, probiotics appear
as one of the alternatives currently under discussion
[15]. That probiotics may shorten the time of diarrhoea
and therefore the time of rotavirus excretion [11,15] is
of epidemiological relevance and deserves study.
Although there are several probiotic strains that could
be used for treatment, in daily practice we are often lim-
ited by the type and number of products locally avail-
able. In general, information about combined products
is scarce. With this in mind, in this study we compared
the efficacy of two commercially available products, one
containing S boulardii (single species product) and
the other combining L. acidophilus, L. rhamnosus,
B. longum (multiple species product), in children with
rotavirus associated diarrhoea.
Methods
Design
This was a prospective, double blind, randomized proto-
col conducted in children 1 to 23 months of age, hospi-
talized for acute diarrhoea at the Paediatric Centre
Albina Patiño (CPAP) between July 2007 and February
2008 in Cochabamba - Bolivia. These children were
evaluated for rotavirus, as well as for bacterial pathogens
and parasites. Parents received detailed information
about the study and those who agreed to participate
signed an informed consent. The protocol was reviewed
and approved by the Ethics Committee of CPAP; also,
we explained the study in detail to the professionals in
charge of the patients care such that they would be
motivated and willing to follow the protocol strictly.
Operational definition of acute diarrhoea was defined
as the presence of at least three bowel movements more
than the normal number for the child and/or presence
of watery stools per day, plus a latex test positive for
rotavirus within 24 hour prior to hospitalization or
within 6 hours after hospitalization. Exclusion criteria
were Weight/Height (WHO standards, 2006,) [16] at or
below -3SD, dehydration >10% (because patients
received iv fluids), severe electrolytic imbalance (hypoka-
lemia <3.5 mEq/L, hypernatremia < 145 mEq/L), detec-
tion of bacterial and/or parasitic agents of diarrhoea in
the stools, detection of other infections (sepsis, pneumo-
nia, urinary infection), diagnosis of immune deficiency,
administration of antibiotics, anti diarrheal drugs or pro-
biotics during the 7 days prior to admission to the
protocol.
On admission to the study data about full clinical his-
tory, physical examination, nutritional status, dehydra-
tion, fever, oral tolerance, and stools characteristics,
were recorded. After the patient clinically stabilized and
maintained hydration for at least 3 hours (within
approximately 24 hours), cases were randomized to one
of three groups (figure 1): Group GC received oral rehy-
dration solution (ORS) and a placebo, Group GB
received ORS plus S boulardii and group GARLB
received ORS plus the combined probiotic product
L. acidophilus, L. rhamnosus, B. longum and S. boulardii
(table 1). Placebo and probiotic products had similar
colour and taste. They were administered for 5 days,
twice daily, dissolved in 20 ml of water, as indicated by
the manufacturer. During the first 48-72 hours the
patients remained in hospital; then the attending physi-
cian decided when the child was discharged, on the
basis of the his/her clinical condition and absence of
diarrhoea, vomiting or fever. After discharge the infants
were monitored once a day until 5 days of treatment
were completed. Controls was performed at the hospital,
by the attending physician, recording probiotic intake,
frequency and appearance of stools, presence of fever
and other relevant clinical features.
Diet
All children received the same diet; those below
6 months of age maintained breast feeding, adding
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only when the mother could not be present. After
6 months of age and in addition to breast feeding and
formula, infants were offered porridge prepared with
chicken, rice, and vegetables (carrots and potatoes).
Variables
The study variable was defined as length of diarrhoea (in
hours), from admission to the first formed stool; pre-
sence of stools and their consistency was checked every
four hours, classifying them in liquid, semi-liquid, soft
and formed. Secondary variables were vomiting (mea-
sured in hours from admission to the last recorded
emesis), duration of fever (> 38°C rectal temperature,
measured every six hours from admission to discharge).
Height was measured in centimetres on admission and
discharge; weight was measured every eight hours using
a scale with 0.5 g increments and up to 15 kg capacity.
Procedures
Blood count included haemoglobin and peripheral white
blood count and differential formula; determination of
semi quantitative CRP was performed using the com-
mercial kit Humatex® CRP(Human Gessellshaff, Wies-
baden, Germany); sodium, potassium and calcium in
plasma using Photometry using Sherwood® Model 410
Classic Flame Photometer Range (Sherwood Scientific
Limited, Cambridge, UK); latex test for rotavirus using
Rida® Quick Rotavirus/Adenovirus Combi (R-Biopharm
AG, Darmstadt, Germany) and parasitological assess-
ment by PAF technique by Lugol method [17]. Stool
culture was performed for enteropathogenic, toxigenic,
enteroadherent, enteroaggregative, invasive and entero-
hemorrhagic Ec o l i , Salmonella typhi and Shigella sp,
Figure 1 Flow Diagram. Flow of participants through trial.
Table 1 Micro organisms load according to the
manufacturer, administration, and main characteristic of
probiotic products analyzed
Group Microorganisms Dose (twice daily) Price ($)*
GARLB L. acidophilus, 6.625 × 10
7 lyophilized cells/dose 8.71
L. rhamnosus, 3.625 × 10
7 lyophilized cells/dose
B. longum, 8.75 × 10
6 lyophilized cells/dose
S. boulardii 1.375 × 10
7 lyophilized cells/dose
GB S. Boulardii 4×1 0
10 lyophilized cells/dose 11.43
*Price corresponds to complete treatment course at the time of the study.
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Agar, SS agar and Tetrahionate Broth Base. Bacto
Difco®, Kansas, USA).
Sample size
This was calculated using the data published by Guarino
[18], who described the effects of a product that com-
bined three probiotics in children with rotavirus diar-
rhoea and found that diarrhoea decreased from 120 ±
30 to 96 ± 30 (24 hours decrease); using 0.8 power, 0.05
(one-sided) significance and assuming 24 hours differ-
ence between the experimental and control groups the
sample size was calculated as 20 cases per group.
Statistical analysis
This included the comparison between the control and
each of the intervention groups and between the two
intervention groups, using non parametric Kruskall-
Wallis testing for comparison of medians in continuous
variables and Mann-Whitney U test. Chi square was
applied to categorical variables. An additional analysis
compared the control group with the merged interven-
tion groups, using Mann - Whitney U test. Data were
processed using Microsoft excel and STATA 1.0
Results
As shown in the algorithm (figure 1), a total of 194 chil-
dren below 2 years of age were admitted during the
study period; 76 fulfilled the protocol inclusion and
exclusion criteria; 12 patients were excluded from analy-
sis: in six, other etiologic agents were found together
with rotavirus (amoebas = 4, Shigella sp=2 ) ;2p a t i e n t s
developed E coli associated urinary infection; in one
pneumonia was diagnosed; one developed bilateral
oedema and kwashiorkor; 2 patients developed severe
vomiting for several days and maintained electrolytic
imbalance; thus, the final number of patients analyzed
was 64. General characteristics of patients excluded
were not different from those that completed the study
period (data not shown).
Sex, age and characteristics of diarrhoea prior to
admission appear in table 2.
Total duration of diarrhoea was significantly shorter in
children receiving S boulardii (P = 0.04) and the
decrease observed in those receiving GARLB was non
significant (P = 0.06) (table 3); differences were not sig-
nificant either between the two intervention groups
(table 3). Although the number of children with fever
was similar in the three groups, duration of fever was
significantly shorter in the group receiving Sb o u l a r d i i
(as compared to controls) (P = 0.0042), whereas no
changes were observed in group GARLB (also compared
to controls). In the same way, the number of children
with vomiting was not different between the three
groups, but group GARLB showed vomiting for a signif-
icant shorter time than controls (P = 0.041) (table 2).
Diarrhoea, vomiting or other complications were
detected after hospital discharge (data not shown).
When the merged intervention groups were compared
with controls (Table 4), total duration of diarrhoea,
fever and vomiting were significantly shorter, (P = 0.025,
P = 0.025 and P = 0.014, respectively).
Discussion
Results show that S boulardii diminished the time of
diarrhoea by 31.4% and shortened time with fever by
73% (table 3). Children receiving the multiple species
product tended to have less time with diarrhoea and no
patients vomited after the treatment was started. In
Table 2 Basal characteristics of groups and secondary outcomes
GC Group
n= 20
GARLB Group
n=2 3
GB Group
n=2 1
P value
Boys (%) 9 (45) 15 (65) 12 (57) 0.40*
Age, months (IQR) 11 (8.5) 6 (5) 8 (7) 0.08
†
Weight, gr. (IQR) 7775 (1769.5) 7652.5 (2765) 7800 (2115) 0.92
†
Duration(IQR) of diarrhoea before treatment (hours) 48 (24) 72 (36) 48 (48) 0.17
†
Median hours of hospitalization (IQR) 89.5 (117) 72 (36) 60 (41) 0.31
₤
N° (%) of children with fever 19 (95) 21 (91) 18 (86) 0.59*
Median (IQR) duration of fever (hours) 67 (60) 48 (36) 18 (53) 0.0042
†
N° (%) of children vomiting 13 (65) 10 (43.5) 11 (52.4) 0.37*
Median (IQR) duration of vomiting (hours) 42.5 (69.5) 0 (25) 4 (44) 0.041
‡
Patients’ characteristics on admission. Duration of hospitalization, of fever and of vomiting after treatment.
IQR= Intercuartile Range
* Chi square test
† Kruskall - Wallis test
₤ Kruskall - Wallis test, adjusted p value, median comparison between GC and GB groups.
‡ Kruskall - Wallis test, adjusted p value, median comparison between GC and GARLB groups.
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ducts similar to the one we used, other authors found a
rather more pronounced effect, 30 hours [14,19] and
30-36 hours reduction in diarrhoeal duration [20-23], in
comparison with the 26 hours reduction we found.
Infants hospitalized in our study were admitted with
severe diarrhoea and had intense clinical manifestations
in comparison to outpatients with rotavirus diarrhoea;
this could explain the less intense results obtained.
Although not significant, we consider relevant the trend
to diminish time of diarrhoea in the group receiving the
multiple probiotic products, because decreasing severity
of diarrhoea may help reducing the nutritional impact
of the diarrhoeal episode.
Other factors such as poor nutritional status, severe
diarrhoea, severe dehydration, should not be confound-
ing variables in this protocol because they were all
exclusion criteria. Reports in the literature about chil-
dren with rotavirus diarrhoea refer mainly to cases man-
aged as outpatients. This study provides evidence that
probiotics are also helpful in cases with less than 10%
dehydration that require hospitalization. It is worth not-
ing that in this study, despite one day less of diarrhoea,
the total length of hospital admissions did not decrease.
This was mainly due to requests of mothers and fathers
to maintain the child one more day under observation
in hospital because, living far from hospital; they feared
their child would need to be readmitted to hospital.
Effects of probiotics on vomiting are not clear. Some
studies have reported no effects [24] whereas other
authors report a significant decrease on time of
vomiting [25] or a transitory effect, observed only during
some days of the episode [26]. Our results support the
effect of probiotics on vomiting, showing decreased time
of vomiting in the intervention groups as compared
with controls (zero versus 40 hours). However only in
the multiple species product-treated group the shorter
time of vomiting reached significance. Furthermore,
children receiving the single species product had almost
50 hours less fever than the control group. This last fea-
ture is in contrast to studies by other authors and also
the results of a study conducted in our hospital compar-
ing Nitazoxanide to probiotics, none of which detected
less time with fever [27].
This study compared two probiotic products, both
readily available in Bolivia, one with a single species of
probiotic bacteria and the other with multiple species of
probiotic bacteria. The former contains higher total con-
centrations of bacteria despite having only one species
and yielded better results. This raises the question as to
whether larger doses of one probiotic bacterial strain are
more efficient than multiple species in smaller numbers.
The effect of different probiotic species and strains on
diarrhoea is currently well accepted [28-32]; however,
the dose required to obtain the best results is less clear.
In a recent study by Fang et al [33]L. rhamnosus
reduced faecal excretion of rotavirus in a dose depen-
dent fashion; authors concluded that the minimal dose
required to have a positive effect was at least 6 × 10
8
CFU, which coincides with other authors [34]. In a
recent metanalysis by Guandalini [31] the recommended
dose was at least 5 × 10
9 CFU. Other authors found no
Table 3 Principal Outcome
Group Treatment Median (IQR) duration (hrs.) *p value
GARLB L. acidophilus, L. rhamnosus, B. longum, S. boulardii 60 (40) 0.06
†
GB S. boulardii 58 (41) 0.04
†
GC Control group 84.5 (94) ————
Duration of diarrhoea after treatment.
IQR= Intercuartile Range
* p value: comparison of median with control group.
† U Mann - Whitney test.
Table 4 Comparison of the merged intervention groups with controls
Control Group
n= 21
Intervention Group*
n=4 3
p value**
Median hours of hospitalization (IQR) 89.5 (117) 76 (48) 0.13
Median hours of diarrhoea (IQR) 84.5(94) 60(40.5) 0.025
Median (IQR) duration of fever (hours) 67 (60) 46.5 (50.5) 0.025
Median (IQR) duration of vomiting (hours) 42.5 (69.5) 0 (33) 0.014
Duration of diarrhoea, hospitalization, fever and vomiting
IQR= Intercuartile Range
* = Intervention group represents the addition of the two groups receiving probiotic products
**Mann - Whitney U Test
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7 L. rhamno-
sus [28]. When we analyzed the products used in our
study, we found that the mixture of probiotics included
a total amount of bacteria of 1.25 × 10
9; estimating the
individual dosing of each probiotics present, they were
well below the amount described as effective. The fact
that we found positive effects on time of diarrhoea, of
vomiting and of fever suggests that the total amount of
bacteria present in the product indeed influences the
results, but it also suggests that adequate numbers, as it
was the case of the single probiotic, yields better results
than a mixture in lesser numbers. Discussing the dose
provided by each commercial product is relevant
because there is evidence suggesting that the effect
obtained is dose dependent [32,35], the higher the dose
the clearer effect. However, studies of adverse reactions
a l s os e e mr e l a t e dt op r o b i o t i cd o s i n g ,t h e r e f o r e ,t h e
appropriate amounts of bacteria should be established
for each probiotic when administered in mixtures, such
as that they are best inducing the effect and at the same
time are safe for the patient.
Conclusions
In summary, results of this study support the use of
probiotics in treating rotavirus diarrhoea. They would
be especially relevant in societies where diarrhoea and
malnutrition have high prevalence; decreasing time of
diarrhoea, of vomiting and of fever will help diminishing
(and/or preventing) malnutrition secondary to acute
diarrhoea.
However, studies of adverse reactions also seem
related to probiotic dosing, therefore, the appropriate
amounts of bacteria should be established for each pro-
biotic when administered in mixtures, such as that they
are best inducing the effect and at the same time are
safe for the patient.
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